Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

220 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial.
Abhishek A, Peckham N, Pade C, Gibbons JM, Cureton L, Francis A, Barber V, Williams JAE, Appelbe D, Eldridge L, Julier P, Altmann DM, Bluett J, Brooks T, Coates LC, Rombach I, Semper A, Otter A, Valdes AM, Nguyen-Van-Tam JS, Williams HC, Boyton RJ, McKnight Á, Cook JA; VROOM study investigators. Abhishek A, et al. Lancet Rheumatol. 2024 Feb;6(2):e92-e104. doi: 10.1016/S2665-9913(23)00298-9. Epub 2023 Dec 12. Lancet Rheumatol. 2024. PMID: 38267107 Free article. Clinical Trial.
Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis.
Jani M, Chinoy H, Warren RB, Griffiths CE, Plant D, Fu B, Morgan AW, Wilson AG, Isaacs JD, Hyrich K, Barton A; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate Collaborators. Jani M, et al. Arthritis Rheumatol. 2015 May;67(8):2011-9. doi: 10.1002/art.39169. Arthritis Rheumatol. 2015. PMID: 26109489 Free PMC article.
Intercritical circulating levels of neo-epitopes reflecting matrixmetalloprotease-driven degradation as markers of gout and frequent gout attacks.
Valdes AM, Manon-Jensen T, Abhishek A, Jenkins W, Siebuhr AS, Karsdal MA, Doherty S, Zhang W, Richardson H, Doherty M, Bay-Jensen AC. Valdes AM, et al. Among authors: abhishek a. Rheumatology (Oxford). 2016 Sep;55(9):1642-6. doi: 10.1093/rheumatology/kew235. Epub 2016 Jun 2. Rheumatology (Oxford). 2016. PMID: 27256715 Clinical Trial.
220 results